Combined therapy in MCL: less may be more?

Dreyling, Martin (2016): Combined therapy in MCL: less may be more? In: Blood, Vol. 128, No. 14: pp. 1782-1783

Abstract

In this issue of Blood, Albertsson-Lindblad et al report on the efficacy of a bendamustine (B)/lenalidomide (LEN)/rituximab (R) combination in first-line therapy of mantle cell lymphoma (MCL). Essentially, this combination achieved high response rates (complete response, 64%;molecular remission, 36%) and a prolonged median progression-free survival (PFS) of 42 months, but rate of infections (42%) and secondary malignancies (16%) were significant. 1 So how should we evaluate these results in light of other trials?

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 0006-4971
• Language: English